Atrium Therapeutics Inc (RNA)
Atrium Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing RNA-based therapies aimed at the heart. The company’s research efforts center on cardiomyopathies and related genetic and cardiac diseases. Its development-stage candidates include ATR 1072, a siRNA therapy designed to target PRKAG2 for PRKAG2 syndrome, and ATR 1086, a siRNA therapy directed at PLN for PLN cardiomyopathy. Atrium Therapeutics was incorporated in 2025 and is headquartered in San Diego, California. The company’s common stock is listed on NASDAQ under the symbol RNA.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-RNA
|
$11.13
|
24.4% Upside
|
Undervalued
|
$25
|
179.3% Upside
|
Bargain
|
Fair
|
0.0%
|
December 2, 2026
|
0.8x
|
4.6x
|
153.1 M
|
-98.687 M
|
1.0%
|
88.2%
|
10.6
|
85.6%
|
